Final answer:
Secondary endpoints in phase III trials can include determining dose-response relationship, evaluating pharmacokinetic profile, and assessing long-term safety.
Step-by-step explanation:
Secondary endpoints in phase III trials can include:
- Determination of a clear dose-response relationship in target population and subpopulations
- Determination of the pharmacokinetic profile of new formulations
- Assessing the long-term safety and the effect of the new drug in specific subgroups of patients through postmarketing risk management trials